Literature DB >> 18095097

Substance P receptor in U373 MG human astrocytoma cells activates mitogen-activated protein kinases ERK1/2 through Src.

Keisuke Yamaguchi1, Toyoki Kugimiya, Toyo Miyazaki.   

Abstract

Substance P (SP) acting through substance P receptor (SPR) increases the proliferation of glioblastoma cells. At the molecular level, stimulation of SPR in human U373 MG glioblastoma cells results in phosphorylation of mitogen-activated protein kinases ERK1/2. Examination of the underlying mechanism reveals that SPR mediates ERK1/2 phosphorylation in a calcium-dependent manner. Surprisingly, blockade of epidermal growth factor receptor (EGFR), which is transactivated by SPR, has a minimal effect on SPR-mediated ERK1/2 phosphorylation. However, SPR-mediated ERK1/2 phosphorylation is significantly reduced by the Src kinase inhibitor PP2. Interestingly, ERK1/2 in U373 MG cells is also activated by several other mitogenic G protein-coupled receptors (GPCRs) including alpha(1B)-adrenergic, M(3)-muscarinic, and H(1)-histaminergic in an Src-dependent manner. We conclude that c-Src is a mediator of SP-stimulated ERK1/2 phosphorylation in human U373 MG glioblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 18095097     DOI: 10.1007/s10014-005-0178-1

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  15 in total

1.  β-Arrestin 1 has an essential role in neurokinin-1 receptor-mediated glioblastoma cell proliferation and G2/M phase transition.

Authors:  Yi-Xin Zhang; Xiao-Fang Li; Guo-Qiang Yuan; Hui Hu; Xiao-Yun Song; Jing-Yi Li; Xiao-Kang Miao; Tian-Xiong Zhou; Wen-Le Yang; Xiao-Wei Zhang; Ling-Yun Mou; Rui Wang
Journal:  J Biol Chem       Date:  2017-03-24       Impact factor: 5.157

2.  Association of the GNB3 825T-allele with better survival in patients with glioblastoma multiforme.

Authors:  Nicolai El Hindy; Michael Adamzik; Nicole Lambertz; Hagen S Bachmann; Karl Worm; Rupert Egensperger; Ulrich H Frey; Siamak Asgari; Ulrich Sure; Winfried Siffert; I Erol Sandalcioglu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-10       Impact factor: 4.553

3.  Substance P activates both contractile and inflammatory pathways in lymphatics through the neurokinin receptors NK1R and NK3R.

Authors:  Sanjukta Chakraborty; Zhanna Nepiyushchikh; Michael J Davis; David C Zawieja; Mariappan Muthuchamy
Journal:  Microcirculation       Date:  2011-01       Impact factor: 2.628

4.  Development of Pyrazolo[3,4-d]pyrimidine Kinase Inhibitors as Potential Clinical Candidates for Glioblastoma Multiforme.

Authors:  Chiara Greco; Vincenzo Taresco; Amanda K Pearce; Catherine E Vasey; Stuart Smith; Ruman Rahman; Cameron Alexander; Robert J Cavanagh; Francesca Musumeci; Silvia Schenone
Journal:  ACS Med Chem Lett       Date:  2020-02-13       Impact factor: 4.345

5.  Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.

Authors:  Sarah E Wheeler; Elena M Morariu; Joseph S Bednash; Charlton G Otte; Raja R Seethala; Simion I Chiosea; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2012-04-06       Impact factor: 12.531

Review 6.  Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Authors:  Manmeet S Ahluwalia; John de Groot; Wei Michael Liu; Candece L Gladson
Journal:  Cancer Lett       Date:  2010-12-08       Impact factor: 8.679

Review 7.  The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells.

Authors:  Hossein Javid; Fariba Mohammadi; Elnaz Zahiri; Seyed Isaac Hashemy
Journal:  J Physiol Biochem       Date:  2019-08-01       Impact factor: 4.158

8.  Involvement of SRC family kinases in substance P-induced chemokine production in mouse pancreatic acinar cells and its significance in acute pancreatitis.

Authors:  Raina Devi Ramnath; Jia Sun; Madhav Bhatia
Journal:  J Pharmacol Exp Ther       Date:  2009-02-11       Impact factor: 4.030

9.  Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question.

Authors:  Richard E Kast
Journal:  Clin Transl Oncol       Date:  2009-07       Impact factor: 3.405

Review 10.  Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach.

Authors:  Cristóbal Belda-Iniesta; Javier de Castro Carpeño; María Sereno; Manuel González-Barón; Rosario Perona
Journal:  Clin Transl Oncol       Date:  2008-02       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.